We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Novavax (NVAX - Free Report) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%. At the same time, the Dow lost 1.01%, and the tech-heavy Nasdaq lost 0.47%.
The the stock of vaccine maker has fallen by 9.17% in the past month, lagging the Medical sector's gain of 4.6% and the S&P 500's gain of 2.6%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. It is anticipated that the company will report an EPS of -$0.67, marking a 53.47% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $90.72 million, reflecting a 68.86% fall from the equivalent quarter last year.
It is also important to note the recent changes to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2899.99% higher. Novavax is currently sporting a Zacks Rank of #2 (Buy).
From a valuation perspective, Novavax is currently exchanging hands at a Forward P/E ratio of 100.25. This denotes a premium relative to the industry's average Forward P/E of 23.12.
It is also worth noting that NVAX currently has a PEG ratio of 2.88. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.67 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Novavax (NVAX - Free Report) ended the recent trading session at $7.92, demonstrating a -1.25% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 0.43%. At the same time, the Dow lost 1.01%, and the tech-heavy Nasdaq lost 0.47%.
The the stock of vaccine maker has fallen by 9.17% in the past month, lagging the Medical sector's gain of 4.6% and the S&P 500's gain of 2.6%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. It is anticipated that the company will report an EPS of -$0.67, marking a 53.47% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $90.72 million, reflecting a 68.86% fall from the equivalent quarter last year.
It is also important to note the recent changes to analyst estimates for Novavax. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 2899.99% higher. Novavax is currently sporting a Zacks Rank of #2 (Buy).
From a valuation perspective, Novavax is currently exchanging hands at a Forward P/E ratio of 100.25. This denotes a premium relative to the industry's average Forward P/E of 23.12.
It is also worth noting that NVAX currently has a PEG ratio of 2.88. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.67 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 67, which puts it in the top 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.